Kerala faces crisis as rehab centres for drug-addicted children struggle amid funding delays
As per the data released by the Excise Department, as part of the Vimukthi project, the number of children coming to Vimukthi centres have gone up in recent years. In 2024, around 2,880 children were treated at Vimukthi de-addiction centres. This year, as many as 588 children sought treatment as of February in Kerala.
The state government decided to open two centres jointly with NGOs exclusively for children back in 2021 under the National Action Plan for Drug Demand Reduction (NAPDDR) by the Ministry of Social Justice and Empowerment. The Samrudha Care Centre for Children in Changanassery is the facility for boys and since its launch, this 25-bedded facility has treated around 260 children.
T M Mathew of Samrudha Care Centre for Children said that, 'We are getting umpteen number of calls everyday. All beds are occupied. Many children are coming here with a history of multiple drug abuse and it takes time to recover,' said T M Mathew. He said that the government owes grants to the tune of over Rs 1. 5 crore to the facility.
'At present, Changanassery Archdiocese and Changanassery Social Service Society are advancing the running cost. Apart from the grant received when we launched, the government hasn't released the grant,' said T M Mathew.
These centres offer three months of regular counselling, medication, yoga, sports, arts therapy, personality development classes and group therapy to help children regain their lives from addiction.
Director Father Joseph Parecattil of Nirmal Nikedhan Mukthi Sadan, de-addiction centre for minor girls, said that they are unable to cater to the growing demand for rehabilitation among children. 'We are offering treatment for girls above 10 years of age. We have only 20 beds and we have treated around 360 children since its launch. Now people are more aware of drug abuse and hence the number of enquiries have gone up,' said Father Joseph. He said that the government owes around `1.28 crores as grant to the institute.
Meanwhile, an official of the Department of Social Justice said that the state is unable to claim the grant from the Centre owing to technical reasons. 'We have already taken up this matter with the Centre. In the recent meeting, we raised this issue as rehab facilities for children is becoming the need of the hour,' said the official.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
2 hours ago
- Indian Express
Opposition alleges Maharashtra govt purchased cancer diagnostic vans at inflated price, Speaker Rahul Narvekar orders inquiry
Maharashtra Assembly Speaker Rahul Narvekar Thursday directed the public health department to conduct an inquiry into the purchase of eight cancer diagnostic vans and submit its findings before the end of the Monsoon Session after the Opposition's allegations. Opposition MLAs questioned the price at which each of the vans was purchased. 'As per the information I have, the price of each van was Rs 99 lakh, while a similar van of the Tata company can be purchased at Rs 45 lakh only. The entire purchase process looks managed and there can be no denying this,' said Shiv Sena (UBT) MLA Bhaskar Jadhav. Meghana Sakore-Bordikar, Minister of State for Public Health, stated that the purchase of eight cancer diagnostic vans was made through the government's GeM portal via a turnkey process. The rates at which purchases were made were 0.94 per cent less than the estimated rates. There was a competitive tender for the same. It involves the vehicle, medical equipment, furniture and customisation. There has been no corruption in the purchase,' said the minister. She said three companies had participated in the tender process. 'At present, an inquiry is ongoing based on complaints from the legislators,' she said. 'The government has purchased eight cancer diagnostic vans. The price of a van cannot exceed Rs 40 lakh. The equipment in this van is not more than Rs 12 lakhs. However, the vehicles have been purchased at a higher price,' said Congress MLA Vijay Wadettiwar. Wadettiwar said these vans are related to a life-threatening disease like cancer, and some of the equipment has even broken down. 'There should be an investigation into whether there has been corruption in this purchase. The report must come out if the investigation is ongoing,' he said. The Congress MLA asked the Speaker to ensure that the report is tabled before the house, before the end of the session. 'The inquiry must be conducted at the earliest and the report should be tabled before the House before the end of the session,' said Speaker Narvekar.
New Indian Express
4 hours ago
- New Indian Express
Telangana to emerge as premier health tourism hub: CM Revanth Reddy
HYDERABAD: Chief Minister A Revanth Reddy on Wednesday said Telangana is fast becoming a leading healthcare hub in India, thanks to premier hospitals and advanced medical infrastructure. Inaugurating the new 300-bed multispecialty branch of AIG Hospitals at Banjara Hills, he said the government is committed to promoting health tourism and accessible healthcare. The chief minister said health tourism will be a key focus in the upcoming Telangana Rising 2047 policy. Health and education remain top government priorities, with Rs 11,500 crore allocated to health and Rs 21,500 crore to education in this fiscal year, he added. Currently, the state provides free medical care of up to Rs 10 lakh for the poor. To boost preventive healthcare, health profile cards with unique IDs will be issued to women in self-help groups, Revanth said, adding that top experts like Dr Nori Dattatreya have been empanelled to strengthen healthcare delivery. Docs urged to serve in govt hosps for at least a month The chief minister highlighted Hyderabad's strong air connectivity with Middle Eastern nations, making it a top destination for medical tourists. He urged doctors to serve in government hospitals for at least one month as social responsibility and called on public hospitals to match private sector standards.
Business Standard
4 hours ago
- Business Standard
Biocon's biologics arm gets regulatory approval in EU for Denosumab biosimilars
Biocon said that Biocon Biologics has received the European Commission (EC) marketing authorisation in the European Union (EU) for Vevzuo and Evfraxy biosimilars of Denosumab. Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). RANKL plays a crucial role in the formation, function, and survival of osteoclasts, which are the cells responsible for bone resorption. By blocking RANKL, denosumab effectively inhibits the breakdown of bone, leading to increased bone mass and strength. Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of bone. Evfraxy is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures or treatment of bone loss associated with long-term systemic glucocorticoid therapy in adults. Clinical data showed that both Denosumab biosimilars have comparable quality, safety, and efficacy to the reference product. The marketing authorisation follows a positive opinion issued by the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025. Shreehas Tambe, CEO & managing director, Biocon Biologics, said: The approval of Vevzuo and Evfraxy in Europe underscores our strong scientific expertise and commitment to expanding patient access to essential medicines, including to new therapeutic areas such as bone health. In the past 18 months, we have successfully secured regulatory approvals for three biosimilars in Europe and two in the UK. These Denosumab biosimilars mark another significant milestone in our rapid expansion, and support for healthcare systems in the region. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The companys consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip shed 0.20% to currently trade at Rs 367.65 on the BSE.
